Biomarkers for predicting the development of gestational diabetes mellitus (meta-analysis)
AbstractGestational diabetes mellitus (GDM) is a common complication in pregnancy, affecting 5% to 9% of pregnancies. Nowadays there is no consensus regarding an optimal and internationally acceptable test for both GDM diagnosis and screening. There is growing concern over the increasing incidence of GDM and its complications for individual mothers and infants along with its impact on society. A simple and accurate blood test that will help identify women at risk of developing GDM in the first trimester can reduce further costs and improve results through early prevention and treatment. Meta-analysis consists studies of 5 major biomarkers that have prognostically significant value for the diagnosis of GDM in early pregnancy. The authors sought to identify the most significant and reliable biomarker that can be used as a screening test for the diagnosis of GDM in the first trimester of pregnancy. Of the 5 biomarkers, adiponectin, GSPG and glycated fibronectin can be independent predictors of GDM in the first trimester. These biomarkers have shown high specificity and sensitivity. The use of three biomarkers at the same time significantly increases the efficiency of forecasting GDM.
Keywords:gestational diabetes mellitus, I trimester of pregnancy, adiponectin, glycated hemoglobin, glycated fibronectin, C-reactive protein, sex hormone binding globulin
For citation: Lee K.I., Pak V.E. Biomarkers for predicting the development of gestational diabetes mellitus. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie [Obstetrics and Gynecology: News, Opinions, Training]. 2019; 7 (3). Supplement: 71-3. doi: 10.24411/2303-9698-2019-13909 (in Russian)